Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3).
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
24
06
2019
revised:
13
09
2019
accepted:
04
11
2019
pubmed:
14
11
2019
medline:
12
1
2021
entrez:
14
11
2019
Statut:
ppublish
Résumé
Laterality of epithelial ovarian tumors may reflect the underlying carcinogenic pathways and origins of tumor cells. We pooled data from 9 prospective studies participating in the Ovarian Cancer Cohort Consortium. Information on measures of tumor size or tumor dominance was extracted from surgical pathology reports or obtained through cancer registries. We defined dominant tumors as those restricted to one ovary or where the dimension of one ovary was at least twice as large as the other, and nondominant tumors as those with similar dimensions across the two ovaries or peritoneal tumors. Competing risks Cox models were used to examine whether associations with reproductive and hormonal risk factors differed by ovarian tumor dominance. Of 1,058 ovarian cancer cases with tumor dominance information, 401 were left-dominant, 363 were right-dominant, and 294 were nondominant. Parity was more strongly inversely associated with risk of dominant than nondominant ovarian cancer ( These data suggest that reproductive and hormonal risk factors appear to have a stronger impact on dominant tumors, which may have an ovarian or endometriosis origin. Examining the associations of ovarian cancer risk factors by tumor dominance may help elucidate the mechanisms through which these factors influence ovarian cancer risk.
Sections du résumé
BACKGROUND
Laterality of epithelial ovarian tumors may reflect the underlying carcinogenic pathways and origins of tumor cells.
METHODS
We pooled data from 9 prospective studies participating in the Ovarian Cancer Cohort Consortium. Information on measures of tumor size or tumor dominance was extracted from surgical pathology reports or obtained through cancer registries. We defined dominant tumors as those restricted to one ovary or where the dimension of one ovary was at least twice as large as the other, and nondominant tumors as those with similar dimensions across the two ovaries or peritoneal tumors. Competing risks Cox models were used to examine whether associations with reproductive and hormonal risk factors differed by ovarian tumor dominance.
RESULTS
Of 1,058 ovarian cancer cases with tumor dominance information, 401 were left-dominant, 363 were right-dominant, and 294 were nondominant. Parity was more strongly inversely associated with risk of dominant than nondominant ovarian cancer (
CONCLUSIONS
These data suggest that reproductive and hormonal risk factors appear to have a stronger impact on dominant tumors, which may have an ovarian or endometriosis origin.
IMPACT
Examining the associations of ovarian cancer risk factors by tumor dominance may help elucidate the mechanisms through which these factors influence ovarian cancer risk.
Identifiants
pubmed: 31719062
pii: 1055-9965.EPI-19-0734
doi: 10.1158/1055-9965.EPI-19-0734
pmc: PMC6954293
mid: NIHMS1542650
doi:
Substances chimiques
Contraceptives, Oral
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-207Subventions
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182934
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES000260
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182913
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL143034
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL080467
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES044005
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA182913
Pays : United States
Organisme : NHLBI NIH HHS
ID : RC1 HL099355
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL043851
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA154337
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES044005-10
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA047988
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Am J Epidemiol. 2010 Jan 1;171(1):45-53
pubmed: 19910378
Biometrics. 1995 Jun;51(2):524-32
pubmed: 7662841
Obstet Gynecol. 2003 Jan;101(1):164-6
pubmed: 12517662
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1511-22
pubmed: 20501754
J Ovarian Res. 2012 May 15;5(1):13
pubmed: 22587442
Histopathology. 2008 Aug;53(2):127-38
pubmed: 18298580
Ann Oncol. 2019 Feb 1;30(2):303-309
pubmed: 30576422
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
Gynecol Oncol. 2009 Jun;113(3):391-6
pubmed: 19237187
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Int J Epidemiol. 2013 Apr;42(2):579-89
pubmed: 23569193
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
pubmed: 10469746
Am J Epidemiol. 2005 Feb 15;161(4):321-9
pubmed: 15692075
Am J Surg Pathol. 2009 Mar;33(3):376-83
pubmed: 19011565
Fertil Steril. 2009 Apr;91(4):975-8
pubmed: 18353324
Gynecol Oncol. 2012 Jan;124(1):164-9
pubmed: 22032835
Lancet Oncol. 2008 Dec;9(12):1191-7
pubmed: 19038766
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
pubmed: 9839517
Hum Pathol. 2011 Jul;42(7):918-31
pubmed: 21683865
Int J Cancer. 2013 Aug 1;133(3):730-9
pubmed: 23364849
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
J Clin Oncol. 2008 Sep 1;26(25):4160-5
pubmed: 18757330
Gynecol Oncol. 2005 Feb;96(2):520-30
pubmed: 15661246
Cancer Causes Control. 2015 Apr;26(4):601-8
pubmed: 25771796
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Hum Reprod. 2013 May;28(5):1406-17
pubmed: 23315066
Int J Cancer. 2019 Jul 1;145(1):58-69
pubmed: 30561796
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190